Skip to main content

Table 2 PVT1 expression and clinical characteristics in patients with hyperparathyroidism

From: Role of LncRNA score and PVT1 in primary hyperparathyroidism-- a preliminary study

Clinical characteristics Low-PVT1
(n = 29)
High-PVT1
(n = 28)
P-value
Age (SD)(years) 59.4 (13.4) 57.1 (12.6) 0.500
Sex (% M) 31.0 39.3 0.585
Disease course (SD) (month) 64.2 (92.3) 78.7 (96.6) 0.576
Cause of first diagnosis (%) With any discomfort 48.3 78.6 0.028#
  discomfort in Bone system 31.0 35.7 0.783
  Nephrolith 13.8 17.9 0.730
  Discomfort in Digestive system 6.9 7.1 1.000
  Thyroid nodular 17.2 7.1 0.423
  Elevated Ca2+ level 24.1 25.0 1.000
Clinical manifestation (%) Bone system 62.1 71.4 0.576
  Nephrolith 48.3 32.1 0.283
  Digestive system 17.2 39.3 0.082
Laboratory examination iPTH (SD) (pg/mL) 442.2 (482.3) 713.0 (690.5) 0.091
  Ca2+(SD) (mmol/L) 2.76 (0.33) 2.97 (0.42) 0.036*
  Albumin adjusted Ca2+(SD)(mmol/L) 2.73 (0.36) 2.98 (0.42) 0.021*
  P (SD)(mmol/L) 0.88 (0.43) 0.79 (0.33) 0.370
  ALP (SD) (U/L) 144.0 (223.3) 218.0 (297.9) 0.292
Imaging location consistent with histopathology (%, n) Tc-99 m-MIBI 88.9 (18) 77.8 (18) 0.658
  Contrast enhanced CT 64.3 (14) 70.00 (10) 1.000
  Thyroid ultrasound 70.8 (24) 72.2 (18) 1.000
Histopathology Maximum diameter (SD) (cm) 2.01 (1.34) 2.58 (1.24) 0.103
  parathyroid cancer (%) 0 39.3 0.000#
LncRNA score (SD) 37.8 (8.9) 62.0 (46.9) 0.008*
  1. *P < 0.05 for Independent Student’s t-test; # P < 0.05 from χ2 test